Alzheimer's Disease Neuroimaging Initiative
The ADNI study tracks the progression of the disease using biological markers (biomarkers; for example, chemicals found in blood, or changes to the brain observed in MRI and PET scans), together with clinical measures (cognitive and neuropsychological tests), to assess the brain’s structure and function over the course of three disease states (cognitively normal/unimpaired, mild cognitive impairment, dementia). ADNI provides study data and biospecimens (samples) to qualified researchers worldwid
Basic Information
- Category: science project
- Website: http://www.adni-info.org/
Documented Facts
- Email: webmaster@loni.usc.edu (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore science project profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Alzheimer's Disease Neuroimaging Initiative.
- Canonical profile: https://brandsource.ai/brands/alzheimer-s-disease-neuroimaging-initiative
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/alzheimer-s-disease-neuroimaging-initiative/json-ld
- Citation profile API: https://brandsource.ai/api/brands/alzheimer-s-disease-neuroimaging-initiative/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
The ADNI study tracks the progression of the disease using biological markers (biomarkers; for example, chemicals found in blood, or changes to the brain observed in MRI and PET scans), together with clinical measures (cognitive and neuropsychological tests), to assess the brain’s structure and function over the course of three disease states (cognitively normal/unimpaired, mild cognitive impairment, dementia). ADNI provides study data and biospecimens (samples) to qualified researchers worldwid
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.